ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Enhancing Olaparib's anti-cancer potential using nanostructured lipid carriers: formulation, evaluation, and in-vitro biological impact.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanostructured lipid carriers (NLCs) containing olaparib (OLA) were designed and refined to enhance effectiveness against Triple Negative Breast Cancer (TNBC) in this study. The OLA-loaded NLC formulation was prepared by melt emulsification followed by ultrasonication. The formulation optimization was performed using a Box-Behnken design in DoE. The optimized NLCs consist of Gellucire® 50/13 as the solid lipid component, Labrafac® MC 60 as the liquid lipid, and Pluronic F 127 and PEG 400 as surfactants. Characterization of the optimized formulation revealed favourable physicochemical properties, including an average particle size of 126.0 ± 4.61 nm, a polydispersity index of 0.2 ± 0.012, a zeta potential of - 13.6 ± 1.21 mV, an entrapment efficiency of 88.5 ± 5.42%, and a drug loading of 14.8 ± 2.74%. Drug release kinetics indicated that the optimized NLC system provided sustained OLA delivery, with 84.49 ± 2.2% cumulative release over 72 h, contrasting significantly with unformulated OLA, which exhibited complete release within just 24 h. Compared with plain OLA, studies using MDA-MB-231 (TNBC) cell lines revealed that the optimized olaparib-loaded NLCs produced considerably greater efficacy (p < 0.05). These results suggest that nanostructured lipid carriers hold substantial promise for boosting the therapeutic efficacy of olaparib.
Indexed as
Identifiers
41511541What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.